New DEADLY Drug Cover-Up (Must Read)

Every drug comes with a risk.

It’s the manufacturer’s job to be upfront about those risks… and it’s your doc’s job to warn you about them… and it’s your job to understand them.

Because when drug information is handled this way, you can make the best possible decision about your health.

Well, that’s what’s supposed to happen.

But it’s NOT happening. 

Because a new report found that drug manufacturers are leaving key findings on the safety and efficacy of drugs.

And it could be a matter of life and death.

A recent review of randomized drug trials published throughout 2016 found some DOWNRIGHT ALARMING trends.

It showed that researchers were consistently using words like “tolerable,” “favorable,” “acceptable,” “manageable,” and even “safe” to describe adverse events.

What kind of adverse events are we talking about here?

They include everything from causing hospital admission and disability, to surgery and life-threatening conditions…and even death.

Does that sound “favorable” or “safe” to you?

Out of 122 cancer drug trials, here’s what they found:

• 14 did not include any data on serious adverse events
• 22 did not include data on serious events
• 2 presented no data on deaths.

And in those that did include data on harm, the results were shocking:

• The rates of serious adverse events were 77% higher in the drug group than in the placebo group
• The number of serious adverse events were 84% higher in the drug group.
• And the DEATHS were 66% higher in the drug group!

No wonder they want to leave out those “inconvenient” truths!

Here’s one example.

In a clinical trial on the breast cancer drug ribociclib, the authors wrote that “most patients had an acceptable adverse-event profile.”

The reality?

More than TWICE the patients taking the drug had a significant adverse event (Grade 3 or higher), compared to those taking a placebo.

Grade 3 means that it was severe or medically significant, or that it could cause disability or hospitalization.

Grade 4 means life-threatening.

These studies were published in journals like the Journal of the American Medical Association, the New England Journal of Medicine, the Journal of Clinical Oncology, and even the Lancet!

We’re talking about some of the most well-respected and prestigious journals out there!

The authors of this revealing study call this “poor reporting practice.” I call it criminal negligence – especially when the possibility of death is on the line.

Of course, the argument is that most cancer patients would gladly take the risk of adverse events for the potential benefits offered by the drugs.

And maybe that’s the case.

But shouldn’t you be given that option? 

Strike that – you SHOULD be given that option.

Anything less is unethical and unacceptable.

To a brighter day,

Dr. Richard Gerhauser, M.D.